Celalettin Eroglu

Celalettin Eroglu

Auto-generated profile, based on publicly available information

Celalettin Eroglu

Department of Radiation Oncology, Erciyes University Medical Faculty, Kayseri, Turkey

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2013 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
CECelalettin Eroglu
Celalettin Eroglu
CPCigdem Pala
Cigdem Pala
LKLeylagul Kaynar
Leylagul Kaynar
KYKadir Yaray
Kadir Yaray
MAM. Tarkan Aksozen
M. Tarkan Aksozen
AUAli Unal
Ali Unal
Conditioning regimens used during stem cell transplant provide prolonged control or cure of the disease in patients with acute lymphoblastic leukemia (ALL). In this study, we present a comparison of treatment results for 95 patients with ALL who underwent allogeneic hematopoietic stem cell transplant (AHSCT) with total body irradiation plus cyclophosphamide (TBI + Cy) or busulfan plus cyclophosphamide (Bu + Cy) as conditioning regimen. Median age was 25 (range: 9–54) years. Median follow-up was 24 (range: 3–107) months. Median overall survival (OS) was found to be 29 months. Median event-free survival (EFS) was 9 months. Median OS was 37 months in the TBI + Cy arm, while it was 12 months in the Bu + Cy arm, suggesting a significant advantage favoring the TBI + Cy arm (p = 0.003). Median EFS was 13 months in the TBI + Cy arm, while it was 4 months in the Bu + Cy arm, indicating a significant difference (p = 0.006). In univariate and multivariate analysis, it was found that high OS and EFS were significantly correlated with TBI + Cy conditioning regimen and lack of transplant-related mortality (p < 0.05). The TBI + Cy conditioning regimen was found to be superior to the Bu + Cy regimen in patients with ALL undergoing AHSCT regarding both OS and EFS.

1 December 2013 in Pathology - Research and Practice
Verified
Journal Article
Closed access
DODilek Unal Ozakca
Dilek Unal Ozakca
ATArzu Tasdemir
Arzu Tasdemir
AOArzu Oguz
Arzu Oguz
CECelalettin Eroglu
Celalettin Eroglu
YCYasemin Benderli Cihan
Yasemin Benderli Cihan
SSSerdar Soyuer
Serdar Soyuer

19 September 2012 in European Journal of Cancer Care
Verified
Journal Article
Closed access
PDF file
CEC. Eroglu
C. Eroglu
OOO. Orhan
O. Orhan
HKH. Karaca
H. Karaca
DUD. Unal
D. Unal
MDM. Dikilitas
M. Dikilitas
BKB. Kaplan
B. Kaplan
EROGLU C., ORHAN O., KARACA H., UNAL D., DIKILITAS M., OZKAN M. & KAPLAN B. (2013) European Journal of Cancer Care22, 133–140 The effect of being overweight on survival in patients with gastric cancer undergoing adjuvant chemoradiotherapy The aim of this study was to examine the effect of being overweight on survival in patients with gastric cancer undergoing adjuvant chemoradiotherapy and chemotherapy. In this study 152 patients were evaluated. Radiotherapy dose was 45 Gy given in 5 weeks. 5‐FU 425 mg/m2 and folinic acid 20 mg/m2 were administered weekly during the radiotherapy and four cycles with 4‐week intervals as consolidation chemotherapy after radiotherapy. Patients were assigned into two groups according to their body mass index: overweight (body mass index ≥25 kg/m2) and normal weight (body mass index <25.0 kg/m2). The median overall survival was 39 months vs. 18 months and median disease‐free survival was 27 months vs. 13 months in the overweight and normal‐weight groups respectively (P= 0.004 and P= 0.006 respectively). The 5‐year survival was better in the patients with overweight than those with normal weight (42% vs. 17%; P= 0.004). The overall survival was significantly better with being overweight and early pathological stage (P= 0.016 and P= 0001 respectively). Overall survival, disease‐free survival and long‐term survival in patients with gastric cancer undergoing adjuvant treatment were better in overweight than normal‐weight patients. Moreover, it was shown that body mass index and pathological stage were associated to survival and prognosis.

1 January 2013 in Annals of Thoracic Medicine
Verified
Journal Article
Open access
PDF file
CECelalettin Eroglu
Celalettin Eroglu
OOOkan Orhan
Okan Orhan
DUDilek Unal
Dilek Unal
GDGamze G Dogu
Gamze G Dogu
HKHalit Karaca
Halit Karaca
BKBünyamin Kaplan
Bünyamin Kaplan
Objectives: To evaluate treatment results and toxicities in patients who received concomitant chemoradiotherapy (CRT) followed by consolidation with docetaxel and cisplatin in locally advanced unresectable non-small cell lung cancer (NSCLC). Methods: Ninety three patients were included in this retrospective study. The patients received 66 Gy radiotherapy and weekly 20 mg/m 2 docetaxel and 20 mg/m 2 cisplatin chemotherapy concomitantly. One month later than the end of CRT, consolidation chemotherapy with four cycles of docetaxel 75 mg/m 2 and cisplatin 75 mg/m 2 were administered at each 21 days. Results: Median age of the patients was 57 (range, 30-74). Following concomitant CRT, 14 patients (15%) showed complete and 50 patients (54%) showed partial response (total response rate was 69%). The median follow-up was 13 months (range: 2-51 months). The median overall survival was 18 months (95% confidential interval [CI]: 13.8-22.1 months); local control was 15 months (95% CI: 9.3-20.6 months); progression-free survival was 9 months (95% CI: 6.5-11.4 months). Esophagitis in eight (9%) patients, neutropenia in seven (8%) patients and pneumonitis in eight (9%) patients developed as grade III-IV toxicity due to concomitant CRT. Conclusion: Concomitant CRT with docetaxel and cisplatin followed by docetaxel and cisplatin consolidation chemotherapy might be considered as a feasible, and well tolerated treatment modality with high response rates despite the fact that it has not a survival advantage in patients with locally advanced unresectable NSCLC.

1 August 2012
Verified
Journal Article
Closed access
CECelalettin Eroglu
Celalettin Eroglu
DODilek Unal Ozakca
Dilek Unal Ozakca
ACAysun Cetin
Aysun Cetin
OOOkan Orhan
Okan Orhan
SSSerdar Sivgin
Serdar Sivgin
AOAhmet Oztürk
Ahmet Oztürk